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PharmacokineticsThe biologic fate of the [3H]PEG-moiety incorporated into N8-GP was evaluated based on single i.v. bolus
doses to rats. Furthermore, the 40 kDa [3H]PEG-moiety was given separately to rats by single i.v. bolus
doses, to investigate if the pharmacokinetics were dose-dependent. For both compounds, plasma pharma-
cokinetics, distribution and excretion pathways were investigated, based on total radioactivity measure-
ments ([3H]N8-GP: 0.17–4.1 mg/kg;~1300–30,000 U/kg, PEG load of ~0.03–0.7 mg/kg); ([3H]PEG: 0.6, 1,
12, 100 and 200 mg/kg). The plasma concentration of the intact N8-GP conjugate was also measured by
ELISA. After single i.v. administration to rats, both [3H]N8-GP and [3H]PEG were shown to be widely distributed,
mainly in highly vascularized tissues, with the lowest levels of radioactivity found in the CNS. Though a slow
elimination of radioactivity was observed over the 12-week study period, approximately half of the radioactive
dose of either compound was removed from the body 1 week post-dose. The radioactivity was eliminated mainly
via the kidney into urine but also via the liver into feces, with a larger fraction found in the feces for [3H]N8-GP.
Elimination of the 40 kDa PEG-moietywas shown tobe dose-dependentwith faster elimination at lower dose levels.
The clinical dose of N8-GP provides a substantially lower PEG exposure (50–75 U/kg; PEG load of b0.002 mg/kg)
when compared to the PEG doses investigated in this paper (0.03–200 mg/kg). This may imply an even faster
clearance of the PEG-moiety after N8-GP administration of clinically relevant doses.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hemophilia A, themost common type of hemophilia, is an inherited
bleeding disorder caused by a deﬁciency in, or dysfunction of, coagulation
factor VIII (FVIII). Hemophilia A is often treated by intravenous (i.v.)
injections of either FVIII puriﬁed from human plasma or FVIII produced
using recombinant DNA technology. Based on decades of clinical experi-
ence in severe hemophilia (Nilsson et al., 1992), prophylactic treatment
is currently recommended as the ﬁrst choice of treatment for severeurve; CL, total plasma clearance;
tration at time zero; CMP-NAN,
, central nervous system; EDTA,
unosorbent assay; FIXa, coagula-
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ination half-life; Tris, 2-amino-
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).
. This is an open access article underhemophilia A by the World Federation of Hemophilia (Srivastava et al.,
2013) and theMedical and Scientiﬁc Advisory Council of the National He-
mophilia Foundation (MASAC Recommendation Concerning Prophylaxis.
Document #179, 2007). The scope is to prevent frequent and/or
prolonged bleeding episodes that could otherwise lead to pain, irrevers-
ible joint damage, and life-threatening hemorrhages (Coppola et al.,
2008; Coppola and Franchini, 2013; Hay, 2007).
With currentlymarketed FVIII products generally showing circulatory
terminal half-lives of 12–14 h in man, prophylactic use typically requires
injections every other day or three times weekly, to maintain sufﬁcient
circulating levels of FVIII (Bjorkman et al., 2009; Bjorkman and
Berntorp, 2001). Various technologies have been used to increase
the duration of effect, one being conjugation of therapeutic proteins
with water-soluble polymers such as polyethylene glycol (PEG) (Bailon
and Won, 2009; Harris and Chess, 2003). Several PEGylated therapeutic
proteins are approved for use across a variety of indications, including
chronic diseases (e.g., Cimzia®, Mircera®, and PEGASYS® are all
protein-based compounds conjugated to 30 or 40 kDamolecular weight
[MW] PEGs). The general preclinical and clinical safety aspects of
PEGylated products have been reviewed and discussed elsewhere, with
the conclusion that no PEG-related safety concerns have been identiﬁed
at clinically relevant doses of PEGylated products (Ivens et al., 2013;
Webster et al., 2007; Webster et al., 2009).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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NovoEight®) and a single-branched 40 kDa PEG, has been shown to
have a good safety proﬁle and improved pharmacokinetics (PK) in
hemophilia A patients (Tiede et al., 2013). Site-directed PEGylation
and the PEGylation technology in relation to N8-GP conjugate have
been described elsewhere (DeFrees et al., 2006; Stennicke et al., 2013).
It has been shown that N8-GP has approximately a 1.5–2-fold longer
half-life compared to rFVIII in several species, including the rat
(Stennicke et al., 2013) and a hemophilia A dog model (Agerso et al.,
2012), aswell as in humans (Tiede et al., 2013),with a similar reduction
in systemic clearance observed (5.4 versus 9.4 ml/h/kg in the rat for
N8-GP and rFVIII, respectively). The prolonged half-life is expected
to enable less frequent dosing in humans than for currently used,
non-modiﬁed rFVIII products.
Stennicke et al. showed that binding of N8-GP to immobilized
low-density lipoprotein receptor-related proteins (LRP), an endocytic
receptor family abundantly expressed in the liver, was reduced
compared to FVIII. As LRP has been implicated with selective clearance
of FVIII in the liver (Saenko et al., 1999; Strickland et al., 2014), a protec-
tive role of the PEG-moiety in the binding to LRPmay likely contribute to
the reduced clearance of N8-GP. The same suggested mechanism of
prolongation has also been shown for other PEGylated rFVIII (Mei et al.,
2010; Turecek et al., 2012). At a molecular weight above 170 kDa, FVIII
is not expected to be cleared by the kidneys.
In contrast to the speciﬁc clearance pathway of FVIII, PEG molecules
in general are predominantly excreted unchanged in the urine by renal
ﬁltration, with PEGs of the size used in N8-GP being excreted slowly.
Some biliary excretion may occur, likely via hepatocyte and/or Kupffer
cell uptake in the liver (Cai et al., 2012; Nesbitt et al., 2009; Webster
et al., 2007; Webster et al., 2009; Yamaoka et al., 1994).
The aim of this paper is to describe the biologic fate of [3H]-labeled
N8-GP after single i.v. bolus doses to rats, with focus on the fate of the
40 kDa [3H]PEG-moiety. Furthermore, the 40 kDa [3H]PEG-moiety was
given separately to rats by single i.v. bolus doses, to investigate whether
the PK of [3H]PEG was dose-dependent. For both compounds, the
plasma PK, distribution, and elimination were investigated, based on
total radioactivitymeasurements. Finally, the concentration of the intact
conjugate was also followed in plasma using an enzyme-linked immu-
nosorbent assay (ELISA) speciﬁc to N8-GP.
2. Materials and methods
N8-GP (average MW including the PEG moiety ~219,000 Da) and
glycyl sialic acid cytidine monophosphate(GSC) was supplied by Novo
Nordisk A/S, Måløv, Denmark. Radiolabeled [3H]PEG and [3H]N8-GP
were delivered by Isotope Chemistry at Novo Nordisk A/S. All other
solvents and reagents were of analytic grade and purchased from com-
mercial suppliers.
2.1. Synthesis of radiolabeled tracers
[3H]PEG (a) was prepared in a single step from a 40 kDa PEG precur-
sor capped with an allylic moiety (GL2-400 O-allyl-Bz) (b). Tritium was
incorporated by saturation of the double bond using tritium gas and a
Pd/C catalyst (Fig. 1). High-performance liquid chromatography (HPLC)
analysis was applied to establish radiochemical purity, identity, speciﬁc
radioactivity, and content of residual [3H]40 kDa PEG-Bz.
[3H]N8-GP was synthesized in four steps. In the ﬁrst step,
Allyl-40kPSC (c) was prepared from GL2A-O-allyl-400NP (d) (NOF)
and GSC (e) (Malmstrom, 2012), and in the second step, [3H]40 kDa
PSC (f) was prepared by saturation of the allyl double bound using
tritium gas and Pd/C catalyst (Fig. 1). Then, in the third step, [3H]N8-
GP was synthesized by enzymatic conjugation (Stennicke et al., 2013).
Turoctocog alfa was desialylated by sialidase to yield free O- and
N-glycans, then sialyltransferase (ST3Gal1, supplied by Novo Nordisk
A/S) catalyzed the transfer of sialic-acid-[3H]PEG to O-glycan located inthe B domain of FVIII. Following the anion-exchange chromatography
puriﬁcation step, the remaining free O- and N-glycans were capped
by incubation with ST3Gal3 and cytidine-5′-monophospho-N-
acetylneuraminic acid (CMP-NAN). The radiochemical purity, identity,
and speciﬁc activity were analyzed by HPLC, as described below.
2.1.1. Synthesis procedure for [3H]PEG
In a typical reaction mixture GL2-400 O-allyl-Bz (114 mg), MeOH
(1ml), Pd/C 10% (55 mg), tritium gas (466 GBq) was stirred at ambient
temperature overnight. To remove Pd/C, the mixture was manually
ﬁltered (25 mm Arodish GHP, hydrophilic polypropylene 0.2 μm, Pall
Life Science). The crude product was lyophilized three times (3 × 3 ml
MeOH) and dissolved in water (3 ml). Basic puriﬁcation was accom-
plished by two dialysis steps (Slide-A-Lyzer Dialysis Cassettes
3500MW, Thermo Scientiﬁc,Waltham, MA, USA) against water/sodium
chloride (NaCl) (0.1 M, 1000 ml). The yield was 4.4 GBq.
HPLC analysis was conducted on a Dionex ultimate 3000 HPLC
system (Thermo Scientiﬁc, Waltham, MA, USA) equipped with a
Phenomenex Jupiter C18 column, (3 μm, 300 Å, 4.6 × 250 mm),
Perkin Elmer Packard 150TR radio-ﬂow detector (PerkinElmer,
Waltham, MA, USA), and Shimadzu ELSD-LT-II ELS detector/DAD
detector (Holm & Halby, Brøndby, Denmark). The mobile phases
consisted of A: milli-Q water and B: MeCN. The system was operated
in gradient mode from 10% B to 60% B over 50min at 35 °C. The radio-
chemical purity was N95%; however, a broad peak indicated some
degree of PEG degradation. The identity was conﬁrmed by HPLC
retention time using reference material. The speciﬁc activity was
crudely estimated to 3 TBq/mmol by HPLC (ELS standard curve
versus applied radioactivity), corresponding to roughly three tritium
atoms per molecule. The residual content of PEG-Bz was estimated to
be b5% by HPLC (UV standard curve versus applied tracer).
2.1.2. Synthesis procedure for [3H]N8-GP
Allyl-40 kDa PSC: GL2A-400 O-allyl-400NP (2.0 g) was dissolved in
tetrahydrofuran (THF) (40 ml). This was added to a solution of cytidine
monophosphate-5′-Glycyl-neuraminic acid GSC (0.68 g) dissolved in
2-(N-morpholino)ethanesulfonic acid buffer (80 ml, 0.5 M pH 8). After
30 min, the THF was removed in vacuo and the product was isolated
by ﬁve dialysis steps (as above, against water/NaCl 40 ml 0.1 M, 1-h
intervals). The material was lyophilized overnight and dissolved/
suspended inMeOH (40ml). Afterﬁltration, the productwas precipitated
by addition of diethyl ether (250 ml) and cooling (5 °C). The precipitate
was dried in vacuo (1.8 g) and identity was conﬁrmed by 1H nuclear
magnetic resonance spectroscopy in D2O.
[3H] 40 kDa PSC: Allyl-40 kDa PSC (239 mg) was dissolved in
MeOH (1 ml) and Pd/C 10% (50 mg), and tritium gas (529 GBq)
was stirred at room temperature for 2 h. The crude product was
ﬁltered and lyophilized as described above, and the crude material
was dissolved in buffer N (2 ml, 20 mM His, 10 mM CaCl2, 500 mM
NaCl, glycerol 20% pH 6.1(His buffer) and used in the following
step immediately.
[3H]N8-GP: Turoctocog alfa (2.8 mg/ml) in His buffer (2 ml),
sialidase urifaciens (0.4 mg/ml, 50 μl), St3Gal1 (2.5 mg/ml, 250 μl),
and [3H]40kDa PSC (25mg in 250 μl His buffer) weremixed and reacted
at ambient temperature for 16–20 h. The sample was diluted with a
buffer solution of Tris 25 mM, CaCl2 5 mM, NaCl 20 mM, glycerol 20%,
pH 7.5 (buffer A, 1000 ml), and loaded on a Mono Q 5/50 column
(supplied by GE Healthcare, Buckinghamshire, UK). The material
was eluted with 0.7 M NaCl in buffer A (buffer B), capped with
CMP-NAN and St3Gal3 (CMP-NAN 6 mg in buffer B) and St3Gal3
(1.2 mg/ml, 100 μl), and allowed to react for 0.75 h at ambient temper-
ature. The reaction mixture was puriﬁed as described above.
Buffer exchange was performed with L-histidine (1.5 mg/ml),
CaCl2 (0.25 mg/ml), Tween 80 (0.1 mg/ml), NaCl (18 mg/ml), sucrose
(3 mg/ml), in 1 l H2O (pH 7) on a size exclusion chromatography
using HiLoad 10/600 (supplied by GE Healthcare, Buckinghamshire,
Fig. 1. One-step synthesis of [3H] 40 kDa PEG OH (a) and two-step synthesis of ([3H]PEG) 40 kDa PSC.
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described under synthesis of [3H]PEG) equipped with a Zorbax 300SB
C3 column (5 μm, 300 Å 4.6 × 150 mm; Agilent, Santa Clara, CA). The
mobile phases consisted of A: 0.1% triﬂuoroacetic acid in milli-Q water
and B: 0.09% triﬂuoroacetic acid in water:MeCN (20:80). The system
was operated in gradient mode from 35% B to 100% B over 50 min at
10 °C, radiochemical puritywasN93%, identitywas conﬁrmedbyHPLC re-
tention time using N8-GP reference material, and the speciﬁc activity for
[3H]N8-GPwas assessed using HPLC – it was found to be between 1.8 and
4.4 TBq/mmol, corresponding to 1.5–4 tritium atoms per molecule.
2.2. In vitro activity of [3H]N8-GP
The quality of the [3H]N8-GP was examined by determination of the
speciﬁc FVIII activity and by investigating the binding to immobilizedvon Willebrand factor (vWF). The activity assay measures the cofactor
activity of FVIII in FIXa-mediated activation of FX, in the presence of
phospholipids and calcium. The reagents from the Coatest SP kit
(Chromogenix, Instrumentation Laboratory, Milan, Italy) were used
and the assay was carried out as previously described (Stennicke et al.,
2013). Dilutions of turoctocog alfa and [3H]N8-GP were analyzed in
parallel. Turoctocog alfa, calibrated against the World Health Organisa-
tion (WHO) 8th International Standard Factor VIII Concentrate (NIBSC
code 07/350), was used as standard in the assay. The FVIII activity per
mg protein was calculated by dividing the activity with the protein
concentration, which was determined in an ELISA assay and based on
two anti-FVIII light chain antibodies (AsserachromVIIIC:Ag, Diagnostica
Stago, France).
The calibrator in the ELISA was turoctocog alfa where the protein
concentration was determined by size exclusion chromatography and
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was determined by amino acid analysis as reference.
The binding to immobilized plasma-derived vWFwas determined in
an ELISA as described (Christiansen et al., 2010). The bound FVIII was
detected using a biotinylated in-house anti-FVIII A2 domain antibody
(FVIII-1F5).
2.3. Laboratory animals
All protocols for the in vivo studies were reviewed and approved by
the ethical review council at Novo Nordisk A/S prior to study start. The
in vivo studieswere conducted at Covance under UKhomeofﬁce license
and laboratory procedures fully commensurate with international
standards of good laboratory practices, but without quality assurance
assessment. Male Han Wistar rats (HsdHanTM, WIST), with an initial
weight between 190 and 257 g (7–9 weeks of age) were used in all
studies. Most rats were obtained from Harlan, Blackthorn, UK but rats
used in the tissue distribution study of PEG were delivered by Charles
River UK Ltd. (Margate, UK) due to constraints in delivery of rats of
the right age and size fromHarlan at the time this studywas conducted.
All ratswere housed up toﬁve per cage, in solidﬂoor cages containing
suitable bedding. Rats were single housedwhen theywere in themetab-
olism cages for collection of excreta, and were rehoused in groups in the
time intervals between the collection periods. The rats were kept in
rooms thermostatically maintained at a temperature of 18–24 °C, with
a relative humidity of between 45 and 79% and exposed to ﬂuorescent
light in 12-h cycles. Temperature and relative humidity were recorded
on a daily basis. The facility was designed to give 15–20 air-changes per
hour.
The rats were provided with wooden Aspen chew blocks and
polycarbonate tunnels in order to enrich both the environment and
the welfare of the animals. Though they were not given chew blocks
or tunnels when in glass metabolism cages, they were provided with
glass hoops as an alternative form of environmental enrichment. For
the animals not housed in metabolism cages, the bedding, chew blocks
and tunnels were replaced at the end of the working day on dose day
and again at the end of the next working day. This was done in order
to reduce the potential for contamination and further ingestion of
drug-related material. The rats were allowed free access to commercial
pellet diet and water at all times during the study.
2.4. Experimental design
2.4.1. Excretion recovery and plasma sampling
Male Han Wistar albino rats (n = 3) were dosed with a single
intravenous dose of either [3H]N8-GP (low dose: 0.17 mg/kg,
~1160 U/kg at an activity of 8500 U/mg, PEG load of ~0.03 mg/kg;
high dose: 4.1 mg/kg, ~28,000 U/kg, PEG load of ~0.7 mg/kg) or
40 kDa [3H]PEG (1, 12, 100, or 200 mg/kg). It should be noted that
the exact concentration in U/kg for the highest dose of [3H]N8-GP
is unknown since the in vitro activity was only tested for the lower
dose formulation. The corresponding doses in radioactivity were:
3.5 and 35 MBq/kg respectively for the two doses of [3H]N8-GP and
30–37 MBq/kg for [3H]PEG. All [3H]N8-GP dosed rats were given
higher doses than given therapeutically to humans (50–75 U/kg,
~PEG load of b0.002 mg/kg). This was done in order to secure reliable
detection of radioactivity for up to 12 weeks post-dosing. The rats
were kept in standard glass metabolism cages continuously for the
ﬁrst 3 days of the study period and thereafter for 24-h intervals on a
weekly basis up to 12 weeks.
The samples were prepared in various ways prior to measuring the
total radioactivity using liquid scintillation counting (LSC). Volumes
and/or weights of biologic samples were measured where appropriate.
Plasma, urine, and cagewashingswere added directly to liquid scintillant
prior to LSC. Feces and cage debris were homogenized in an appropriate
volume of deionized water and then solubilized using a suitable volumeof solubilizing agent (Soluene®-350; PerkinElmer LAS [Beaconsﬁeld,
UK]). After an appropriate period of incubation, liquid scintillant was
added and the samples measured by LSC. Carcasses were digested in a
solutionof potassiumhydroxide inmethanol (approximately 40%,weight
per volume) and then measured by LSC. Recoveries of radioactivity were
calculated over time and the total recovery of the administered dose was
estimated by interpolation between the sampling points.
Bloodwas collected from 5min up to 12weeks post-dose at all dose
levels, from the jugular vein. A total of 12 rats (2 × 6 rats) were used for
collection of blood for each compound and dose, with 6 rats sampled at
5min; 1, 6, and 24 h; and 1, 3, 5, 7, 9, and 11weeks post-dose, and 6 rats
sampled at 30 min; 2, 8, and 48 h; and 2, 4, 6, 8, 10, and 12 weeks
post-dose. Blood samples were then pooled per time point.
For [3H]N8-GP, for the ﬁrst 4 weeks following dosing, blood samples
were split in two immediately after withdrawal. One part was collected
in a tube containing tri-sodium citrate as anticoagulant to provide a
pooled blood sample per time point from six animals, with a minimum
of 100 μl plasma needed for exploratory ELISA. The remainder of the
blood sample was collected in a tube containing EDTA as anticoagulant
and subsequent centrifugation (4000 g, 10 min, 20 °C) to provide a
pooled plasma sample per time point from six animals for provision of
plasma for LSC analysis. Pooled plasma samples from [3H]PEG dosed
rats were also obtained using EDTA as anticoagulant and subsequent
centrifugation. Plasma samples from both [3H]PEG- and [3H]N8-GP-
dosed rats were analyzed in duplicate to obtain total radioactivity
count data using LSC.
2.4.2. Tissue distribution
For the quantitative whole body autoradiography (QWBA) studies,
male Han Wistar albino rats (n= 9) were dosed with a single i.v. dose
of either 4.1 mg/kg [3H]N8-GP (35 MBq/kg, ~28,000 U/kg, PEG load of
~0.7 mg/kg) or 0.6 mg/kg [3H]PEG (37 MBq/kg).
Following anesthesia under isoﬂurane, one rat per time point was
sacriﬁced by a 30-min cold shock (plunged into a freezing mixture of
excess of solid CO2 in hexane). Once fully frozen, the carcasses were
prepared for analysis using the QWBA techniques. The sampling time
points were 1, 12, 24, and 96 h, and 1, 2, 5, 9, and 12 weeks post-dose.
Immediately prior to sacriﬁce, a blood sample was taken from each
animal by cardiac puncture and collected into EDTA-precoated tubes;
sampleswere then centrifuged to obtain plasma (4000 g, 10min, 20 °C).
2.4.3. In vivo stability of [3H]PEG and [3H]N8-GP
Plasma samples obtained in relation to the two tissue distribution
studies were divided into two aliquots prior to LSC. One aliquot was
analyzed directly by LSC, the other was freeze-dried, reconstituted in
water and analyzed by LSC to enable the quantiﬁcation of the volatile
tritiated water content in the original sample.
2.4.4. ELISA assay for detection of N8-GP in rat plasma
The sandwich ELISA used to quantify intact N8-GP utilized two
detection antibodies. One antibody was directed against an epitope on
the PEG-moiety and the other against an epitope on FVIII. In brief,
microtiter plates were coated with an anti-PEG antibody (LAGH-2F8)
and free binding sites were blocked using buffer containing 1% bovine
serum albumin and 0.05% Tween 20. Prediluted calibrators and samples
were further diluted 1:5 in rat EDTA plasma, and added to the coated
plates together with a HRP conjugated detection antibody directed
against FVIII (BDD-FVIII-1F10). After washing of the plates, a peroxidase
substrate buffer was added; this contained a chromogenic reagent,
Tetramethylbenzidine (3,3′,5,5′-Tetramethylbenzidine), allowing for
quantiﬁcation of N8-GP conjugate present in the samples.
2.5. Pharmacokinetic analysis
Plasma radioactivity concentration versus time data from the excre-
tion balance and the QWBA studies were used to assess the distribution
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single i.v. doses of [3H]PEG or [3H]N8-GP. The radioactive concentrations
were transformed to nmol equivalents/g plasma using the speciﬁc
activity of the respective radioactive formulations (simpliﬁed to nmol/l
or nM throughout this paper).
Due to the unspeciﬁcity of using total radioactivity measurements,
challenges in interpreting the resulting pharmacokinetic (PK) parame-
ters exist. It is for example not a certainty that the PK analysis of plasma
radioactivity from [3H]PEG-dosing solely represents the intact 40 kDa
PEG as the results may represent the kinetics of a mixture of intact
PEG and any metabolites formed over the sampling period. However,
as a 40 kDa PEG is generally considered to be a metabolically stable
compound ((Webster et al., 2007); see also ‘the discussion’), it is
deemed likely that the majority of plasma radioactivity measured in
this study after i.v. dosing of [3H]PEG can be attributed to the intact
40 kDa PEG.
Assessment of [3H]N8-GP-related plasma radioactivity is further
complicated by the fact that the compound is a conjugate of two entities
with vastly different kinetics, meaning that themeasured plasma radio-
activity is likely to represent different ratios of intact [3H]N8-GP and
[3H]PEG, or any metabolites, at different time points.
For the reasons described above, the PK evaluation of plasma radio-
activity should be interpreted with some caution. However, for the
purposes of this study it was still deemed useful to describe the disposi-
tion of the total radioactive dose quantitatively to be able tomake some
simple comparisons between different dose levels of [3H]PEG and
between [3H]PEG- and [3H]N8-GP-related plasma radioactivity.
To assess the kinetics of the intact N8-GP conjugate after [3H]N8-GP
i.v. dosing, plasma concentrations fromELISAmeasurementswere used.
As the blood samples were collected in a sparse sampling design,
mean composite plasma proﬁles were produced from pooled samples
(“naïve pool method”; n= 6/time point) for each compound and dose
level prior to noncompartmental analysis (NCA). The PK parameters
assessed by NCA were the back-extrapolated concentration at time
zero (C0), terminal elimination half-life (t½) (based on linear regression
of the log-linear terminal phase), mean residence time (MRT), total
plasma clearance (CL), volume of distribution at steady-state (Vss),
and the areas under the concentration-time curves from time zero to
time t (AUC(0–t)), and from zero to inﬁnity (AUC). The extrapolated
area (AUCextrap) from the last sampling time point to inﬁnity was also
estimated.
To further assess the observed dose-dependency in the kinetics of
the total plasma radioactivity after various i.v. dose levels of [3H]PEG, a
standard open 2-compartment i.v. bolus ﬁrst-order elimination model
was explored. Here, the volumes of the central and peripheral distribu-
tion compartments (Vc and Vp), the inter-compartment distribution
clearance (CLd) and CL were estimated. A proportional error model
was used for ﬁtting the model to the plasma concentration data.
All PK analyses were performed in Phoenix™WinNonlin® version
6.2 (Pharsight, St. Louis, MI).
3. Results
3.1. In vitro activity of [3H]N8-GP
The FVIII activity of [3H]N8-GP was 8500 U/mg, close to the value
obtained for the N8-GP starting material (i.e., 11,000 U/mg), indicating
that [3H]N8-GP had retained close to full FVIII in vitro activity (~80%).
[3H]N8-GP showed retained capability of binding to vWF as the binding
afﬁnity of [3H]N8-GP to vWF was similar for [3H]N8-GP and turoctocog
alfa.
3.2. In vivo stability of [3H]PEG and [3H]N8-GP
To assess any potential in vivo stability issue, [3H]PEG and [3H]N8-GP
tracers were evaluated via determination of the amount of 3H2O inplasma samples. None to very low amounts of tritiated water in plasma
were generated for both tracers up to 12 weeks post-dose.
3.3. Tissue distribution of [3H]PEG
The tissue distribution of [3H]PEG after i.v. administration was
followed for up to 12 weeks post-dose. Radioactivity was widely
distributed,mainly in the highly vascularized tissues, andwas gradually
eliminated (Fig. 2A).
Peak concentrations of radioactivity typically occurred at 1 or 12 h
post-dose (ﬁrst and second sample), with more than nine out of ten
investigated tissues containing peak concentrations of radioactivity at
these time points. Tissues containing the highest levels of radioactivity
were, in order of magnitude: urine, blood, lungs, bile ducts, lymph,
adrenal glands, and kidneys. Radioactivitywas detectable in themajority
of tissues up to 5 weeks post-dose and at the ﬁnal sampling time point
(week 12) radioactivity was still widely distributed, with approximately
one-third of the tissues still containing low levels of quantiﬁable radioac-
tivity. The tissues in the central nervous system (CNS) (brain and spinal
cord) were exposed to low levels of drug-related material and only
quantiﬁable at the two earliest time points after dose administration
(1 and 12 h).
3.4. Tissue distribution of [3H]N8-GP
The radioactivity in rat tissues after i.v. administration of [3H]N8-GP
waswidely distributed and gradually eliminated (Fig. 2B). Radioactivity
was distributed at low levels throughout thewhole body intomore than
50 tissues in the male rat. Peak concentrations of radioactivity typically
occurred at the 1-, 12-, and 24-h sampling times, with about 75% of the
investigated tissues containing peak concentrations of radioactivity at
these times. The highest levels of radioactivity were found in highly
vascularized tissue/organs, with the highest levels of radioactivity
detected in (in order ofmagnitude): plasma, blood, lymph, liver, spleen,
bile ducts, lungs, kidneys, and adrenal glands. Approximately half of
the tissues contained quantiﬁable levels of radioactivity at the ﬁnal
sampling time (12 weeks), with the highest amounts in lymph, liver,
and spleen. Low levels of radioactivity (close to the detection limit)
were present in the CNS (brain and spinal cord) at all time points,
with the last data point measured at 5 weeks post-dose.
3.5. Excretion of [3H]PEG
The estimated total recoveries for the four excretion studies
performed with [3H]PEG were between 88 and 93% (Table 1).
[3H]PEG-related radioactivity was excreted in both urine and feces,
with urinary excretion as the major route of elimination (75%, 73%,
56%, and 62% excreted in urine 12 weeks post-dose for the 1 mg/kg,
12mg/kg, 100mg/kg, and 200mg/kg, respectively). The fraction excreted
in feces was similar for all four dose levels (~10% of the radioactive dose).
In contrast, the lower doses of [3H]PEG seemed to provide increasing
fractions excreted in urine (Table 1; Fig. 3). The majority of radioactivity
(N50%) of each of the four doses was excreted within 1 week post-dose
but some radioactivity still remained to be excreted at the last time
point (5–20%; 12 weeks post-dose). The fraction that remained in the
carcass after 12 weeks seemed to be dependent on dose – it was higher
with increasing dose. Low levels of radioactivity were still being excreted
at the ﬁnal time point (0.05–0.1% per day).
3.6. Excretion of [3H]N8-GP
The average interpolated excretion recovery for [3H]N8-GP was
found to be 78% for the 4.1 mg/kg dose and 104% for the 0.17 mg/kg
dose (see Table 1). The reason for the difference in total recovery is
unknown. PEG-related radioactivity was excreted both in urine and in
feces, though the percent of dose excreted in the urine at the low dose
Fig. 2.Tissue/organdistribution of radioactivity related to [3H]PEG (A) or [3H]N8-GP (B) at 1, 12, 24, and96h, and 1, 2, 5, 9 and12weeks post-dose after a single intravenous administration
at a dose of 0.6 mg/kg [3H]PEG and 4.1 mg/kg [3H]N8-GP (~PEG load of 0.7 mg/kg) in Wistar rats (n= 1 per time point).
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of dose excreted in feces was similar at the two dose levels (~35%).
Furthermore, in total, approximately 50% of the radioactive dose was
excreted during the ﬁrst 1 or 2 weeks post-dosing. Only a small amount
of radioactivity remained to be excreted at the ﬁnal time point of
12 weeks post-dose (5.6% and 7.7% for the 0.17 mg/kg and 4.1 mg/kg
doses, respectively). PEG-related radioactivity was still being excreted
at a low rate (~0.2% per day) at this time.3.7. Pharmacokinetics after i.v. dosing of [3H]PEG
The PK of [3H]PEG-related plasma radioactivity was investigated
in the rat after single i.v. bolus administration of 0.6, 1, 12, 100, and
200 mg/kg [3H]PEG. The evaluation was based on total radioactivity
measurements converted to nmol equivalents per liter. As discussed
above, the PK evaluation was interpreted with the assumption that the
total plasma radioactivity after dosing of 40 kDa [3H]PEG is mainlyTable 1
Estimated excretion recoveries (%) following single intravenous bolus doses of [3H]PEG or [3H]
[3H]PEG (% of dose)
200 mg/kg 100 mg/kg 12 mg/kg 1 mg/kg
Urinea 62.4 55.5 73.3 74.8
Feces 12.0 12.4 13.4 12.6
Carcass 18.2 20.3 6.1 5.4
Total 92.6 88.2 92.8 92.8
a Cage wash is included in urine.attributed to the intact molecule throughout the study; the PK evalua-
tion should be interpreted with this in mind.
The mean composite plasma proﬁles of total radioactivity from the
different [3H]PEG dose levels are shown on a semi-logarithmic scale in
Fig. 4a. The proﬁles appeared to display a biphasic decay after i.v. dosing
at all ﬁve dose levels, with an initial decline in concentrations over the
ﬁrst 1 or 2 weeks, where after a slower terminal phase was observed
until the end of the experiment 12weeks post-dose. Atweek 12, detect-
able levels of radioactivitywere still present in plasma for all dose levels.
Though the most obvious difference between the plasma concen-
tration versus time proﬁles was seen for the lowest [3H]PEG dose of
0.6 mg/kg compared to the higher dose levels (especially from
dose-normalized data; Fig. 4b), possibly caused by a higher clearance
of radioactivity after the 0.6 mg/kg dose, there was also evidence of a
slower terminal elimination phase after the 100 and 200mg/kg doses
versus the 1 and 12 mg/kg doses. Notably, even though substantially
longer terminal t½ for the plasma radioactivity were estimated after
the two highest dose levels (42–59 days) compared to the two lowerN8-GP.
[3H]N8-GP (% of dose)
4.1 mg/kg N8-GP ~0.7 mg/kg PEG 0.17 mg/kg N8-GP ~0.03 mg/kg PEG
34.4 62.7
37.5 33.4
5.6 7.4
77.5 104
Fig. 3.Cumulative excretion results of radioactivity for the highest (200mg/kg) and lowest
(1 mg/kg) dose of [3H]PEG (n= 3 per time point).
Fig. 4.Total plasma radioactivity concentrations, converted to nmol equivalents/l (or nM), for
single intravenous bolus doses to rats of 0.6, 1, 12, 100, and 200 mg/kg [3H]PEG or 0.17 and
4.1 mg/kg [3H]N8-GP. (A) Semi-log plot; (B) semi-log plot of dose-normalized data (n= 6
rats per time point, except for the 0.6 mg/kg dose of [3H]PEG and one of the two 4.1 mg/kg
doses of [3H]N8-GP (red squares) where n = 1 per time point). Data from the two
4.1 mg/kg [3H]N8-GP studies originate from two separate studies: tissue distribution
(red squares) and excretion/plasma sampling (red circles).
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proportional manner between 1 and 200 mg/kg. Though the latter may
not appear to align with a dose-dependent terminal t½, a likely explana-
tion can be found in the fact that a large fraction of the radioactive dose
had already been eliminated before the start of the terminal phase
(40–60% after 1 week; Fig. 3). This means that a major fraction of
the total AUC was not affected by the different terminal rates. For the
0.6 mg/kg [3H]PEG dose, the terminal t½ of radioactivity was estimated
to be 19 days.
FromNCA analysis, the plasma clearance of [3H]PEG-related radioac-
tivity appeared to be similar for doses between 1 and 200 mg/kg, while
the apparent distribution volume of the radioactivity (Vss) was approx-
imately 2-fold higher after the two highest doses (Table 2). This was
also conﬁrmed by ﬁtting a standard 2-compartment model to the
data, which further indicated that the nonlinearity of the total plasma
radioactivity seen for the two highest dose levelswas due to a difference
in the peripheral distribution volumes. Because of the apparent nonlin-
earity observed for [3H]PEG-related radioactivity, one set of parameter
estimates could not adequately explain plasma data from all dose levels
simultaneously in the standard 2-compartment model. For the scope of
the current assessment, being able to comparemodel parameters across
dose levels was deemed sufﬁcient, hence more sophisticated modelswere not explored and the dose levels were modeled individually. The
actual model ﬁt of the data is shown in Fig. 5 and the model parameter
estimates are listed in Table 3.
From the model ﬁt of the plasma radioactivity data, estimation of
total CL and total apparent volume of distribution produced similar
results as the NCA (Table 3). The peripheral volume of distribution
(Vp) for the [3H]PEG-related plasma radioactivity was much larger
than the central volume (Vc). For the two highest dose levels, the
modeling results indicated that an increase in Vp was responsible for
the total increase in the apparent volume of distribution and hence
likely the longer terminal t½ observed at these dose levels compared
to the 1 and 12 mg/kg doses.
There was approximately a 2-fold difference in the estimated Vc
after the 0.6 mg/kg dose level. This is likely an effect of the different
sampling schedule used at this dose level, where fewer early blood
samples were collected after dosing compared to the other dose levels.
Table 2
PK parameter estimates from noncompartmental analysis of total plasma radioactivity after single intravenous bolus doses of 0.6, 1, 12, 100, or 200mg/kg [3H]PEG or 0.17 and 4.1 mg/kg
[3H]N8-GP and plasma concentrations of N8-GP after 0.17 and 4.1 mg/kg [3H]N8-GP.
Parameter/dosed compound (assay) [3H]PEG (LSC) [3H]N8-GP (LSC) N8-GP (ELISA)
Dose (mg/kg) 0.6 1 12 100 200 0.17 4.1a 4.1b 0.17 4.1b
C0 (nM) 114 477 5260 38,900 83,800 35.6 207 413 68.4 375
AUC(0-1wk) (h*nM) 4650 13,500 190,000 1,350,000 2,650,000 331 4190 5160 148 1710
AUC (h*nM) 7340 22,900 360,000 3,180,000 5,750,000 449 7250 9550 148 1710
AUC/dose ((h*nM)/(nmol/kg)) 524 996 1290 1380 1220 569 370 487 188 87.3
AUCextrap (%) 1.3 4.4 5.6 21 14 0.31 0.84 2.5 0.14 0.53
CL (ml/h/kg) 1.9 1.0 0.78 0.72 0.82 1.8 2.7 2.1 5.32 11.4
Vss (ml/kg) 500 430 390 870 690 300 770 790 50.6 103
t½ (days) 19 24 26 59 42 13 14 19 0.2 0.27
MRT (days) 11 18 21 50 35 7.0 12 16 0.40 0.38
aQWBA study. bExcretion balance study. MRT, mean residence time.
Note: sparse sampling design with each sample representing pooled concentrations from 6 rats.
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of the dosed radioactivity from NCA data in Table 2 (dose/C0), where V0
is approximately the size of plasma volume for the doses between 1 and
200 mg/kg, but approximately 2-fold higher for the 0.6 mg/kg. This
difference in V0 is likely caused by an underestimation of the back-
extrapolated C0 due to the described lack of early samples for this
dose level.
The fraction of the administered [3H]PEG dose remaining to be
eliminated from plasma after 12 weeks increased with increasing
dose and was estimated to be approximately 1% for the 0.6 mg/kg
dose, 4–6% for the 1 and 12 mg/kg doses, and 21% and 14% for the
100 and 200 mg/kg doses (AUCextrap; Table 2).
3.8. Pharmacokinetics of [3H]N8-GP-related radioactivity in plasma
The plasma PK of N8-GP was investigated in the rat after single i.v.
bolus administration of 0.17 and 4.1 mg/kg [3H]N8-GP (~1300 and
30,000 U/kg). The evaluation was based on total radioactivity measure-
ments or ELISA concentration measurements of the intact conjugate,
both converted to nmol/l. As discussed earlier the total radioactivity
measurements may represent intact [3H]N8-GP, [3H]PEG or various
radioactive metabolites, with the ratios of these varying over time, the
PK evaluation should be interpreted with this in mind.
The mean composite plasma radioactivity proﬁles from the two
different dose levels are shown on a semi-logarithmic scale in Fig. 4.Fig. 5.Model ﬁt to [3H]PEG-related plasma radioactivity data. A standard 2-compartment
model with linear elimination was used. Due to potential nonlinearity after [3H]PEG i.v.
dosing, individual ﬁts per dose were performed (n = 6 rats per time point, except for
the 0.6 mg/kg dose where n= 1 per time point).As observed for [3H]PEG, the radioactivity proﬁles collected after i.v.
dosing of [3H]N8-GP appeared to display a biphasic decay in plasma
concentrations, with a relatively rapid decline in concentrations during
the ﬁrst week post-dose and a subsequent much slower terminal elim-
ination phase-out to 12 weeks post-dose.
In Fig. 6, the plasma concentration versus time proﬁles of the N8-GP
conjugate (as measured by ELISA) are plotted together with the total
radioactivity proﬁles after dosing of [3H]N8-GP. To better visualize the
ELISA data, only the ﬁrst 14 days post-dose are displayed. It is apparent
that N8-GP exists in plasma as an intact conjugate for up to a few
days following dosing. This is much shorter than that observed for
[3H]PEG-related radioactivity after dosing of [3H]N8-GP. Plasma
clearance was higher, and a lower apparent distribution volume
was estimated by NCA for the conjugate compared to that for total
radioactivity (Table 2), with a terminal t½ for the former estimated
to approximately 5–6 h.
Plasma clearance of total radioactivity appeared to be similar for the
two investigated dose levels; however, the estimated apparent Vss was
almost 2-fold larger following the higher dose (Table 2). The terminal t½
of plasma radioactivity was 13 days for the 0.17 mg/kg dose and
14–19 days for the 4.1 mg/kg doses. Furthermore, the fraction of the
administered radioactive dose remaining to be eliminated from plasma
12 weeks post-dose was estimated to be approximately 0.3% for
the 0.17 mg/kg dose and 0.8–2.5% for the 4.1 mg/kg doses (AUCextrap;
Table 2).
Similarly after [3H]PEG dosing, a large fraction of the administered
[3H]N8-GP-related radioactivity was already eliminated from plasma
after the ﬁrst week of dosing (N70% after 0.17 mg/kg and 50–60% after
4.1 mg/kg) (Table 2).4. Discussion
The distribution and elimination of a novel PEGylated rFVIII (N8-GP)
were assessed in rats over 12 weeks after single i.v. administration of
[3H]N8-GP. Single doses of the 40 kDa [3H]PEG were also assessed.Table 3
Estimated model parameters after ﬁtting a 2-compartment model to total concentrations of
plasma radioactivity after single intravenous bolus doses of 0.6, 1, 12, 100, or 200 mg/kg
[3H]PEG.
Parameter [3H]PEG
Dose (mg/kg) 0.6 1 12 100 200
Vc (ml/kg) 160 (12) 90 (7.5) 81 (5.2) 85 (5.3) 84 (6.6)
Vp (ml/kg) 360 (14) 310 (15) 310 (9.8) 670 (12) 580 (13)
Vtot (ml/kg) 520 (11) 400 (12) 390 (8.1) 760 (11) 670 (11)
CL (ml/h/kg) 1.9 (6.7) 1.0 (6.0) 0.82 (4.2) 0.78 (4.9) 0.89 (5.7)
CLd (ml/h/kg) 1.2 (25) 0.57 (18) 0.68 (15) 0.85 (12) 1.0 (18)
aQWBA study.
bExcretion balance-study.
CV% is stated within brackets.
Fig. 6. Plasma concentrations of total radioactivity (gray triangles and circles) and plasma
concentrations of intact N8-GP (black squares and diamonds) versus time after single
intravenous bolus doses of 0.17 (A) or 4.1 mg/kg [3H]N8-GP (B) to the rat. Radioactive
concentrations were converted to nM. It should be noted that only the ﬁrst 14 days
post-dose are shown to enable better visualization of the ELISA data (n = 6 per time
point for all studies).
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characterize the ADME properties of the PEG-moiety was assessed at
an early stage and resulted in labeling of the PEG-moiety. Labeling the
protein backbone was also considered but would have resulted in a
plasma concentration-time proﬁle resembling the ELISA data of N8-GP
(Fig. 6), and any PK assessment of such data would describe the fate of
intact N8-GP and metabolites, rather than the PEG.
Radiolabelingwith tritiumwas selected in favor of carbon-14, based
on a combination of higher speciﬁc radioactivity and a wish to use
traditional analytic techniques (e.g., QWBA and LSC). In contrast to sim-
ple tritium exchange of labile hydrogen atoms, the current 3H-labeling
was based on speciﬁc and stable aliphatic labeling in the propylic capping
group at the end of each PEG chain. The 3H-labeling of the PEGwas found
to be stable and ﬁt-for-purpose as very little, or no, tritiated water was
detected in plasma samples throughout the studies, thus allowingmean-
ingful assessment of the fate of both [3H]N8-GP and [3H]PEG.
Previous ﬁndings of the plasma kinetics of the intact N8-GP conju-
gate in rats (Stennicke et al., 2013) were conﬁrmed in these studies,
with an N8-GP plasma t½ of 5–6 h, representing the removal and/or
metabolism of intact N8-GP.The plasma proﬁles of total radioactivity appeared to be biphasic
in nature, both after i.v. dosing of [3H]N8-GP and [3H]PEG. Plasma
clearance of [3H]PEG-related radioactivity was higher after dosing
of [3H]N8-GP compared to after dosing of [3H]PEG. Apparent volume
of distribution of radioactivity was fairly large after dosing of either
compound, especially after the higher doses.
Using a simple 2-compartment PK model to describe the plasma
radioactivity after i.v. dosing of [3H]PEG, radioactive material appeared
to be relatively widely distributed to the periphery as seen by a large
estimated Vp. Further, total clearance and distribution clearance of
plasma radioactivity were generally of similar magnitude, indicating
that these were competing processes. Consequently, a substantial
fraction of the radioactive dose would be expected to be cleared before
distribution equilibrium. This was also conﬁrmed by excretion data,
which indicated that at least half of the radioactivity dosed was elim-
inated 1–2 weeks post-dose. This latter ﬁnding was also true for
radioactivity related to [3H]N8-GP dosing. QWBA data showed a wide
distribution of radioactive material for both compounds, particularly to
the highly vascularized tissues, with a gradual decrease in radioactivity
over time.
After distribution equilibrium was reached for plasma radioactivity
around one ([3H]N8-GP) or two ([3H]PEG) weeks post-dose, a slow
terminal elimination phase was apparent. This pattern has also
been observed for other PEGylated compounds such as certolizumab
pegol, a 40 kDa PEG conjugated to a Fab’ (Nesbitt et al., 2009). Judging
by the faster rate of disappearance from plasma of the N8-GP conjugate
(as measured by ELISA) and the similar terminal phases of plasma
radioactivity when [3H]N8-GP or [3H]PEG were dosed at similar PEG-
loads, the slow elimination phase is likely due to [3H]PEG-relatedmate-
rial. Thiswould indicate that the 40 kDa PEG-moiety behaves kinetically
similar after detachment from the rFVIII-moiety as when dosed alone.
In general, the protein part of PEGylated proteins is thought to be
degraded via proteolysis to short peptides and amino acids by lysosomal
enzymes. The PEG and/or PEG and linker are then supposedly released
to the lymphatics and blood (Baumann et al., 2014; Elliott et al., 2012;
Webster et al., 2009). FVIII is believed to be selectively cleared in the
liver via the LRP pathway (Bovenschen et al., 2003; Saenko et al.,
1999; Strickland et al., 2014), but PEGylation of rFVIII has been shown
to delay this interaction, resulting in prolongation of the plasma t½
(Stennicke et al., 2013). PEG is likely also cleared via the LRP pathway
when still attached to rFVIII, as evidenced by the larger fraction of
radioactivity collected in the feces for [3H]N8-GP versus [3H]PEG
(30% vs. 10%).
[3H]PEG-related radioactivity was shown to be mainly cleared via
the kidneys following dosing of [3H]PEG or [3H]N8-GP. PEGs of all MW
are predominantly excreted unchanged in the urine, though at various
rates depending on their size. 40 kDa PEG has been shown to be slowly
eliminated from the body, mainly via renal elimination and likely
by passive ﬁltration (Nakaoka et al., 1997; Woodburn et al., 2013;
Yamaoka et al., 1994). For [3H]N8-GP, though not conﬁrmed in these
studies, it is unlikely that radioactivity found in rat urine would repre-
sent intact N8-GP as both the conjugate and rFVIII have MW much
higher than the reported cut-off for kidney elimination (~70 kDa;
(Caliceti and Veronese, 2003).
As seen by others (Cai et al., 2012; Nesbitt et al., 2009;Webster et al.,
2009), hepatobiliary elimination appeared to be minor for [3H]PEG,
with only a small fraction of radioactivity recovered in feces. Further-
more, 40 kDa PEG is not believed to be extensively metabolized in the
liver (Webster et al., 2007).
Cumulative excreta data of 1 and 200 mg/kg [3H]PEG indicated
similar fecal excretion of radioactivity, but dose-dependent urinary
excretion (Fig. 3). Though the terminal excretion rates between 2 and
12 weeks post-dose were different between the two high doses and
the lower doses, themain distinction appeared to be in the much larger
fraction of radioactivity excreted into urine during the ﬁrst 2 weeks for
the lower doses.
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radioactivity after i.v. dosing of [3H]PEG. This was evident in a slower
terminal elimination rate following the 100 and 200 mg/kg doses com-
pared to the dose levels of 12mg/kg and below. Therewas a ~2-fold lon-
ger terminal t½ for the top doses (42–59 days) versus 1 and 12 mg/kg
(24–26 days) and also a larger fraction of dose remaining to be excreted
from plasma 12 weeks post-dose. The latter observation was further
conﬁrmed by the larger fraction of radioactivity found in the animal
carcasses for the top doses compared to the lower dose levels at week
12 (20% vs. 5%). At 0.6 mg/kg [3H]PEG, an even faster elimination of
radioactivity was indicated compared to the 1 and 12 mg/kg doses.
Overall, the terminal t½ for [3H]PEG was found to be in line with results
published in the literature e.g., for Cimziawhere a t½ ~23 dayswas found
for the 40 kDa PEGmoiety in certolizumab pegol following a s.c. dose of
400 mg/kg (Nesbitt et al., 2009).
Using modeling, one possible explanation compatible with the
observed nonlinearity in [3H]PEG-related radioactivity plasma data
could be a wider peripheral distribution of the dosed radioactivity for
the higher dose levels, with approximately 2-fold larger estimates of
Vp compared to at the lower dose levels.
The low levels of radioactivity that remained to be excreted
12 weeks post-dose for both compounds were detected in several
tissues/organs and were, thus, not conﬁned to one speciﬁc location. The
liver, lymph, and spleen contained much higher levels of radioactivity
following administration of [3H]N8-GP versus [3H]PEG. The higher
concentrations detected in the liver (including bile ducts) could be due
to uptake via LRP.
The relatively high levels of radioactivity observed in the tissues
related to the lymphatic system (lymph, mandibular lymph node, and
spleen) following administration of [3H]PEG, and especially [3H]N8-GP
(Fig. 2), indicate a role for lymphatic uptake in the disposition of PEG
and especially of N8-GP. Interestingly, several publications describe
similar observations for other PEGylated molecules, suggesting that
PEGylation of proteins appears to promote extravasation and subse-
quent reabsorption of the conjugate into the lymphatics via the
interstitial space after i.v. dosing. A relationship between higher
PEGMWand increased lymphatic redistribution has also been described
(Kaminskas et al., 2013; Lamka et al., 1995; Zou et al., 2013).
In conclusion, after single i.v. administration to the rat, [3H]PEG-
related radioactivity was shown to be widely distributed after both i.v.
dosing of [3H]N8-GP and [3H]PEG, mainly in highly vascularized tissues,
with the lowest levels found in the CNS. Though a slow elimination of
radioactivity was observed over the 12-week study period, approxi-
mately half of the radioactive dose of either compound was removed
from the body 1 week post-dose.
The radioactivity was eliminated mainly via the kidneys into urine
but also via the liver into feces, with a larger fraction found in the
feces for [3H]N8-GP compared to [3H]PEG. Elimination of the radioactiv-
ity related to the 40 kDa PEG-moiety was shown to be dose-dependent,
with faster elimination at lower dose levels. The clinical dose of N8-GP
provides a substantially lower PEG exposure (50–75 U/kg; PEG load
of b0.002 mg/kg) when compared to the PEG doses investigated in
this paper (0.03–200 mg/kg). This may imply an even faster clear-
ance of the PEG-moiety after N8-GP administration of clinically rele-
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